Gyros and DI Biotech sign distribution agreement for the Korean market

26-Nov-2009

Gyros AB, the leading provider of automated micro-immunoassays for therapeutic protein development, is pleased to announce the signing of a distribution agreement with DI Biotech, the leading supplier to the Korean life-science market. Under the terms of the agreement, DI Biotech will market and provide full support for Gyros’ proprietary technology to the Korean pharmaceutical, biotech, CRO and CMO industries.

Gyrolab has rapidly become established as the preferred technology for high-performance immunoassays for the development of biotherapeutics. The technology is increasingly employed by leading pharmaceutical and biotech companies, and their contracted service organizations, in their drug development process and clinical trials, in both Europe and the USA. As a result of this success, the company has now decided to expand its business into Asia, with Korea as its initial market.

“We are very happy to have DI Biotech representing our products in the Korean market”, states Erik Walldén, CEO and President of Gyros. “It’s an organization with longstanding experience, presence, and a solid position as a leading supplier of high-tech tools to the biotech market. Korea is committed to the growing biotherapeutics development segment and we are looking forward to supplying enabling technology to various ongoing initiatives in the country,” he concludes.

S. E. Kim, CEO and President at DI Biotech comments: “We have already tested the market for Gyrolab in Korea, and the response was immediate and positive, which was very encouraging. The benefits that Gyrolab provides are recognized in all sectors of pharmaceutical development, as well as in government-funded institutes. Pharma, biotech and especially, the fast-growing CRO and CMO companies, all see possibilities, to not only ramp-up productivity, but also to boost their competitiveness. The financial standing of these industries was already strong, and coupled with the Korean government’s recent investment of the equivalent of 90 million EUR, to further propel the development of biotherapeutics within the ‘SMART project’, we are extremely optimistic about the rapid uptake and implementation of Gyrolab in Korea.”


Enquiries:
For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com
www.zymecommunications.com


Notes to editors:
About Gyros (www.gyros.com)

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.